Halozyme’s “Hat Collector” Approach To Human Capital: Virtue in Versatility
A Q&A on biopharma workforce recruitment, training and C-suite oversight with Halozyme's Ken Schultz, MD. A supplement to our feature on the In Vivo/EBD Academy survey, "Future-Proofing Human Capital in the Global Life Sciences: Does Biopharma Have the Right Stuff?
You may also be interested in...
An interview with Odgers Berndtson's John Hawkins about the credentials needed for the next-gen biopharma C-suite. A supplement to our feature on the In Vivo/EBD Academy survey, “Future-Proofing Human Capital: Does Biopharma Have the Right Stuff?”
In this supplement to our feature on the In Vivo/EBD Academy survey "Future-Proofing Human Capital In Global Life Sciences", Ramona Sequeira, President of Takeda Pharmaceutical's US Business Unit, presents her company’s strategy to anticipate and respond to a disruptive transformation of the industry payer base.
Biopharma's future depends entirely on the application of human ingenuity to complex problems with no easy solutions. In Vivo, with its Informa business solutions partner EBD Academy, recently conducted a survey of industry decision-makers in the US and Europe for recommendations on how to attract talent, boost employee engagement, foster diversity and maintain the product innovation that patients demand and society expects.